3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
117
Carcinoma, Transitional Cell
39
Testicular Neoplasms
23
Urethral Neoplasms
18
Testicular Germ Cell Tumor
14
Ovarian Neoplasms
13
Teratoma
12
Prostatic Neoplasms
11
Endodermal Sinus Tumor
11
Seminoma
10
Neoplasms
10
Carcinoma, Embryonal
9
Ureteral Neoplasms
8
Melanoma
8
Carcinoma, Non-Small-Cell Lung
8
Carcinoma, Renal Cell
7
Stomach Neoplasms
6
Penile Neoplasms
6
Neoplasm Metastasis
6
Colorectal Neoplasms
6
Breast Neoplasms
6
Urologic Neoplasms
5
Sarcoma
5
Pancreatic Neoplasms
5
Urothelial Cancer
4
Lung Neoplasms
4
Central Nervous System Neoplasms
4
Wilms Tumor
3
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Interventions
fluciclovine F-18
2
relatlimab
1
pembrolizumab
1
enfortumab vedotin
1
darolutamide
1
Radiation Dose Hypofractionation
1
Nivolumab
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Diseases
×
Cisplatin
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled